Thank you so much!

I have the same question. I like that you are using a higher quantity of MSC’s, I just want to make sure the quality is as good.

Not at the moment. We want to focus on stem cell medicine and research. Peptide therapies don't have as much research backing them and I've heard too much "hit and miss" from past patients. But adding them shouldn't be an issue if you're interested.

Thank you!

Yes it can. There's been some good research documenting umbilical cord stem cells and psoriasis. Including a case where the psoriasis didn't recur. www.nature.com/articles/s41392-022-01059-y www.ncbi.nlm.nih.gov/pmc/articles/PMC8362539/ www.ncbi.nlm.nih.gov/pmc/articles/PMC9263669/

Do you mean a Hematologic diseases?

Yes

@traviswhitney8482 I had 480 m msc's via IV, injections , injections for trigeminal nerve, bilateral nerve damage, several joints, and C spine/L spine. All done at a reputable place out of the country, but my spouse and I are looking for someone in the USA. Do you treat all joints, discs, trigeminal branches, and issues with osteoarthritis?

@@jennifercarillio8403 Yes, all of those are conditions we're familiar with. We can't legally say we "treat" them.

​@@traviswhitney8482Dr. Joy Kong uses CCs and BioXcellerator uses an actual number....like I had 480 million MSCs. We'd like to try a reputable clinic like yours that uses an actual number of MSCs NOT CCs like other clinics.

We have protocols for MS.

@@InnateHealthcareInstitute How effective are they? For all types? Thank you!!

@@pattischmitz2680 Research on the effectiveness of umbilical cord-derived mesenchymal stem cells (UC-MSCs) for multiple sclerosis (MS) has shown promising results, although more extensive clinical studies are still needed to establish their efficacy conclusively. Any use of UC-MSCs for MS is still considered experimental. Here are some key findings from research studies: Immunomodulatory Effects: Several studies have demonstrated that UC-MSCs possess strong immunomodulatory properties, which can help regulate the abnormal immune response observed in MS. UC-MSCs have been shown to suppress inflammatory processes and promote the activity of regulatory T cells, leading to a reduction in autoimmune attacks on myelin and nerve cells. Reduction in Disease Activity: Clinical trials involving MS patients treated with UC-MSCs have reported a decrease in disease activity, including a reduction in relapse rates and the number of lesions observed on MRI scans. UC-MSC therapy has been associated with a decrease in inflammatory markers and an improvement in clinical symptoms, such as reduced disability scores and improved quality of life. Promotion of Tissue Repair: Preclinical studies have demonstrated that UC-MSCs can promote tissue repair and regeneration in the central nervous system. UC-MSCs have been shown to stimulate remyelination, repair damaged nerve cells, and support the growth of new blood vessels, which may contribute to improved neurological function in MS patients. Safety Profile: Research studies have generally reported a favorable safety profile for UC-MSC therapy in MS patients, with minimal risk of adverse effects. Long-term follow-up studies have not identified any serious safety concerns associated with UC-MSC treatment, although further monitoring is necessary. Challenges and Limitations: While the preliminary results are promising, there are challenges and limitations to consider, including the need for larger, multicenter clinical trials with longer follow-up periods to assess the durability of treatment effects. Standardization of treatment protocols, including cell dose, administration route, and timing, is necessary to optimize the therapeutic potential of UC-MSCs for MS. In conclusion, research suggests that UC-MSC therapy holds promise as a potential treatment option for multiple sclerosis, offering immunomodulatory, regenerative, and neuroprotective effects. However, further well-designed clinical studies are required to establish the efficacy, safety, and long-term benefits of UC-MSCs in the management of MS. In the end it's up to the patient and docotor to decide what's the best course of action.

@@InnateHealthcareInstitute thank you so much for your response.. This is a nasty disease!! Sadly!! Hopefully soon someone will come up with something!!

Are you in the Phoenix area?

@@InnateHealthcareInstitute Florida, but happy to travel.

​@@HiddenCornersOfHumanity We're not doing any research trials at the moment. But you could always call if you have questions about becoming a patient. Or check in to see how progress is going.